These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
730 related items for PubMed ID: 27318420
1. Influences on immunization rates: Vaccination coverage of mumps, measles, rubella and varicella before and after the STIKO intervention 2011 - A retrospective study. Sanftenberg L, Schrörs HJ, Schelling J. Vaccine; 2016 Jul 25; 34(34):3938-41. PubMed ID: 27318420 [Abstract] [Full Text] [Related]
2. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Marin M, Broder KR, Temte JL, Snider DE, Seward JF, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep; 2010 May 07; 59(RR-3):1-12. PubMed ID: 20448530 [Abstract] [Full Text] [Related]
3. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial. Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O. BMJ Open; 2015 Sep 11; 5(9):e007202. PubMed ID: 26362659 [Abstract] [Full Text] [Related]
4. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P. Pediatr Infect Dis J; 2008 Aug 11; 27(8):724-30. PubMed ID: 18600190 [Abstract] [Full Text] [Related]
5. A combination vaccine against measles, mumps, rubella and varicella. Knuf M, Faber J, Barth I, Habermehl P. Drugs Today (Barc); 2008 Apr 11; 44(4):279-92. PubMed ID: 18536786 [Abstract] [Full Text] [Related]
6. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine. Shinefield HR, Black S, Kuter BJ. J Infect Dis; 2008 Mar 01; 197 Suppl 2():S152-5. PubMed ID: 18419390 [Abstract] [Full Text] [Related]
7. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. Leung JH, Hirai HW, Tsoi KK. Expert Rev Vaccines; 2015 Mar 01; 14(8):1149-57. PubMed ID: 26081133 [Abstract] [Full Text] [Related]
8. Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella. Streng A, Liese JG. Vaccine; 2014 Feb 12; 32(8):897-900. PubMed ID: 24412300 [Abstract] [Full Text] [Related]
9. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Nolan T, McIntyre P, Roberton D, Descamps D. Vaccine; 2002 Dec 13; 21(3-4):281-9. PubMed ID: 12450703 [Abstract] [Full Text] [Related]
10. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad. Pediatr Infect Dis J; 2006 Jul 13; 25(7):615-22. PubMed ID: 16804432 [Abstract] [Full Text] [Related]
11. Vaccines for measles, mumps, rubella, and varicella in children. Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Cochrane Database Syst Rev; 2020 Apr 20; 4(4):CD004407. PubMed ID: 32309885 [Abstract] [Full Text] [Related]
12. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P. Eur J Pediatr; 2012 Mar 20; 171(3):463-70. PubMed ID: 21935584 [Abstract] [Full Text] [Related]
13. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context. Casabona G, Berton O, Singh T, Knuf M, Bonanni P. Expert Rev Vaccines; 2023 Mar 20; 22(1):764-776. PubMed ID: 37642012 [Abstract] [Full Text] [Related]
14. The evolution of vaccines for early childhood: the MMRV. Ferrera G, Squeri R, Genovese C. Ann Ig; 2018 Mar 20; 30(4 Supple 1):33-37. PubMed ID: 30062378 [Abstract] [Full Text] [Related]
15. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age. Haas H, Richard P, Eymin C, Fiquet A, Kuter B, Soubeyrand B. Hum Vaccin Immunother; 2019 Mar 20; 15(4):778-785. PubMed ID: 30481110 [Abstract] [Full Text] [Related]
16. Measles-mumps-rubella-varicella combination vaccine (ProQuad): a guide to its use in children in the E.U. Scott LJ. Paediatr Drugs; 2015 Apr 20; 17(2):167-74. PubMed ID: 25732634 [Abstract] [Full Text] [Related]
17. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. Macartney K, Gidding HF, Trinh L, Wang H, Dey A, Hull B, Orr K, McRae J, Richmond P, Gold M, Crawford N, Kynaston JA, McIntyre P, Wood N, Paediatric Active Enhanced Disease Surveillance Network. JAMA Pediatr; 2017 Oct 01; 171(10):992-998. PubMed ID: 28806450 [Abstract] [Full Text] [Related]
19. A new combination vaccine for measles, mumps, rubella and varicella. Zareba G. Drugs Today (Barc); 2006 May 01; 42(5):321-9. PubMed ID: 16801995 [Abstract] [Full Text] [Related]
20. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, Brown ML, Eves KA, Klopfer SO, Schödel F, Kuter BJ. Pediatr Infect Dis J; 2005 Aug 01; 24(8):665-9. PubMed ID: 16094217 [Abstract] [Full Text] [Related] Page: [Next] [New Search]